VERU INC. Proceeds from Notes Payable
VERU INC. (VERU) reported Proceeds from Notes Payable of $1.43 million for the 12-month period ending 2023-09-30, per its 10-K/A filed 2024-04-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2024-05-08
- VERU INC. proceeds from notes payable for the quarter ending 2023-09-30 was $0.00.
- VERU INC. proceeds from notes payable for the quarter ending 2023-06-30 was $0.00.
- VERU INC. proceeds from notes payable for the quarter ending 2023-03-31 was $0.00.
- VERU INC. proceeds from notes payable for the quarter ending 2022-12-31 was $1.43M.
- VERU INC. proceeds from notes payable for fiscal 2023 was $1.43M.
- VERU INC. proceeds from notes payable for fiscal 2021 was $1.06M, a 26.85% increase from fiscal 2020.
- VERU INC. proceeds from notes payable for fiscal 2020 was $836.78K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $0.00 derived: sum of 3 quarters · filed 2024-05-08 | $1.43M 10-K/A · filed 2024-04-01 |
| 2023-06-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-11-15 | $0.00 derived: sum of 2 quarters · filed 2024-05-08 | $1.43M 10-Q/A · filed 2023-11-15 | |
| 2023-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08 | $1.43M 10-Q · filed 2024-05-08 | ||
| 2022-12-31 | $1.43M 10-Q · filed 2024-04-01 | |||
| 2021-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $0.00 derived: sum of 2 quarters · filed 2022-12-05 | $0.00 derived: sum of 3 quarters · filed 2022-12-05 | $1.06M 10-K · filed 2022-12-05 |
| 2021-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-11 | $0.00 derived: sum of 2 quarters · filed 2022-08-11 | $1.06M 10-Q · filed 2022-08-11 | $1.06M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-12 | $1.06M 10-Q · filed 2022-05-12 | $1.06M derived: sum of 3 quarters · filed 2022-05-12 | $1.06M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.06M 10-Q · filed 2022-02-09 | $1.06M derived: sum of 2 quarters · filed 2022-02-09 | $1.06M derived: sum of 3 quarters · filed 2022-02-09 | $1.06M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $0.00 derived: sum of 2 quarters · filed 2021-12-02 | $0.00 derived: sum of 3 quarters · filed 2021-12-02 | $836.78K 10-K · filed 2021-12-02 |
| 2020-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12 | $0.00 derived: sum of 2 quarters · filed 2021-08-12 | $836.78K 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-12 | $836.78K 10-Q · filed 2021-05-12 | ||
| 2019-12-31 | $836.78K 10-Q · filed 2021-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |